Demographics | n | Baseline | n | 18-year follow-up* |
Gender female n (%) | 427 | 290 (67.9) | 427 | 290 (67.9) |
Age at onset of symptoms (years), median IQR | 427 | 5.7 (2.7–9.7) | ||
Time to study visit (years), median IQR | 427 | 0.6 (0.5–0.7) | 427 | 17.6 (16.8–18.4) |
Full-time employed or student, n (%) | 424 | 306 (72.2) | ||
Transferred directly to adult rheum. care, n (%)† | 427 | 163 (38.2) | ||
Transferred later to adult rheum. care, n (%)† | 427 | 60 (14.1) | ||
ILAR category, n (%) | ||||
Oligoarthritis persistent | 427 | 232 (54.3) | 427 | 115 (26.9) |
Oligoarthritis extended | 427 | 85 (19.9) | ||
RF-negative polyarthritis | 427 | 90 (21.1) | 427 | 75 (17.6) |
RF-positive polyarthritis | 427 | 7 (1.6) | 427 | 6 (1.4) |
Enthesitis-related arthritis | 427 | 31 (7.3) | 427 | 41 (9.6) |
Psoriatic arthritis | 427 | 8 (1.9) | 427 | 28 (6.6) |
Undifferentiated | 427 | 45 (10.5) | 427 | 63 (14.7) |
Systemic | 427 | 14 (3.3) | 427 | 14 (3.3) |
ANA positive‡ | 382 | 140 (36.6) | ||
HLA-B27 positive | 410 | 89 (21.7) | ||
Treatment at the visit, n (%) | ||||
NSAID | 417 | 224 (53.7) | 267 | 77 (28.8) |
sDMARD | 427 | 78 (18.3) | 427 | 84 (19.7) |
bDMARD | 422 | 7 (1.7) | 427 | 83 (19.4) |
Disease activity measures | ||||
Number of active joints, median IQR | 427 | 1 (0–3) | 427 | 0 (0–0) |
PhGA, median IQR | 229 | 1.0 (0.5–2.9) | 416 | 0 (0–1.0) |
PaGA, median IQR | 251 | 1.0 (0.1–2.9) | 396 | 0.5 (0–2.5) |
ESR (mm/h), median IQR | 344 | 14 (8–28) | 277 | 5 (2-9) |
cJADAS10 score, median IQR | 222 | 4.4 (1.7–8.5) | 389 | 1.0 (0–4.0) |
CHAQ/HAQ score, median IQR | 260 | 1.0 (0–3.0) | 396 | 0 (0–0.4) |
Pain VAS, median IQR | 247 | 0.3 (0–1.1) | 396 | 0.5 (0–3.0) |
Morning stiffness ≥15 min, n (%) | 418 | 223 (53.3) | 379 | 67 (17.7) |
Uveitis, n (%) | 424 | 19 (4.5) | 427 | 95 (22.3) |
Damage, n (%) | ||||
JADI-A>0 | 258 | 0 | 427 | 69 (16.2) |
JADI-E>0 | 258 | 0 | 427 | 43 (10.1) |
*104 participated through a standardised telephone interview at the 18-year visit. For the 323 patients attending the visit, PaGA was available for 308 and PhGA for 321 participants.
†After the regular follow-up at the paediatric rheumatologist was finished due to age limit, the patient was transferred directly or not to adult care.
‡ANA measured by immunofluorescence on Hep-2 cells, performed at least twice with a minimum of 3 months apart.
A, articular damage (0-72); ANA, antinuclear antibodies; bDMARD, biologic disease-modifying antirheumatic drug; CHAQ/HAQ, Child Health Assessment Questionnaire/Health assessment questionnaire (0–3); cJADAS10, clinical Juvenile Arthritis Disease Activity score (0–30); E, extra-articular damage (0–17); ESR, erythrocyte sedimentation rate; HLA-B27, human leucocyte antigen B27; ILAR, International League of Associations for rheumatology; JADI, Juvenile Arthritis Damage Index; NSAID, non-steroidal anti-inflammatory drug; PaGA, patient or parental global assessment of disease impact on well-being; PhGA, physician’s global assessment of disease activity; RF, rheumatoid factor; sDMARD, synthetic disease-modifying antirheumatic drug; VAS, Visual Analogue Scale (0–10).